Page 793 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 33 Hematopoietic Tumors 771

826. Dewhirst MW, Stamp GL, Hurvitz AI: Idiopathic monoclonal 850. Boostrom BO, Moore AS, DeRegis CJ, et al.: Canine cutaneous
(IgA) gammopathy in a dog, J Am Vet Med Assoc 170:1313–1316, plasmacytosis: 21 cases (2005-2015), J Vet Intern Med 31:1074–
1977. 1080, 2017.
VetBooks.ir 827. Hoenig M, O’Brien JA: A benign hypergammaglobulinemia mim- 851. McHale B, Blas–Machado U, Oliveira FN, et al.: A divergent pseu-
doglandular configuration of cutaneous plasmacytoma in dogs,
icking plasma cell myeloma, J Am Anim Hosp Assoc 24:688–690,
1988.
J Vet Diagn Invest 30:260–262, 2018.
828. Rusbridge C, Wheeler SJ, Lamb CR, et al.: Vertebral plasma cell 852. Mikiewicz M, Otrocka–Domagala I, Pazdzior–Czapula K, et al.:
tumors in 8 dogs, J Vet Intern Med 13:126–133, 1999. Morphology and immunoreactivity of canine and feline extramed-
829. Van Bree H, Pollet L, Cousemont W, et al.: Cervical cord compre- ullary plasmacytomas, Pol J Vet Sci 19:345–352, 2016.
sion as a neurologic complication in an IgG multiple myeloma in a 853. Stilwell JM, Rissi DR: Immunohistochemical labeling of multiple
dog, J Am Anim Hosp Assoc 19:317–323, 1983. myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF-
830. DiBartola SP, Reynolds HA: Hypoglycemia and polyclonal gam- 4) in canine cutaneous histiocytoma, Vet Pathol 55:517–520, 2018.
mopathy in a dog with plasma cell dyscrasia, J Am Vet Med Assoc 854. Baer KE, Patnaik AK, Gilbertson SR, et al.: Cutaneous plasmacy-
180:1345–1349, 1982. tomas in dogs: a morphologic and immunohistochemical study, Vet
831. Villiers E, Dobson J: Multiple myeloma with associated polyneu- Pathol 26:216–221, 1989.
ropathy in a German shepherd dog, J Small Anim Pract 39:249– 855. Clark G, Berg J, Engler SJ, et al.: Extramedullary plasmacytomas in
251, 1998. dogs: results of surgical excision in 131 cases, J Am Anim Hosp Assoc
832. Mitcham SA, McGillivray SR, Haines DM: Plasma cell sarcoma in 28:105–111, 1992.
a cat, Can Vet J 26:98–100, 1985. 856. Kyriazidou A, Brown PJ, Lucke VM: An immunohistochemical
833. O’Keefe DA, Couto CG: Fine–needle aspiration of the spleen as an aid study of canine extramedullary plasma cell tumours, J Comp Pathol
in the diagnosis of splenomegaly, J Vet Intern Med 1:102–109, 1987. 100:259–266, 1989.
834. Werner JA, Woo JC, Vernau W, et al.: Characterization of feline 857. Lucke V: Primary cutaneous plasmacytomas in the dog and cat,
immunoglobulin heavy chain variable region genes for the molecu- J Small Anim Pract 28:49–55, 1987.
lar diagnosis of B–cell neoplasia, Vet Pathol 42:596–607, 2005. 858. Platz SJ, Breuer W, Pfleghaar S, et al.: Prognostic value of histo-
835. Munshi N, Anderon KC: Plasma cell neoplasms. In DeVita V, pathological grading in canine extramedullary plasmacytomas, Vet
Hellman S, Rosenberg SA, editors: Cancer: principles and practice of Pathol 36:23–27, 1999.
oncology, ed 7, Philadelphia, 2005, Lippincott Williams & Wilkins. 859. Rakich PM, Latimer KS, Weiss R, et al.: Mucocutaneous plasmacy-
836. Breitschwerdt EB, Woody BJ, Zerbe CA, et al.: Monoclonal gam- tomas in dogs: 75 cases (1980–1987), J Am Vet Med Assoc 194:803–
mopathy associated with naturally occurring canine ehrlichiosis, 810, 1989.
J Vet Intern Med 1:2–9, 1987. 860. Rowland PH, Valentine BA, Stebbins KE, et al.: Cutaneous plas-
837. Font A, Closa JM, Mascort J: Monoclonal gammopathy in a dog macytomas with amyloid in six dogs, Vet Pathol 28:125–130, 1991.
with visceral leishmaniasis, J Vet Intern Med 8:233–235, 1994. 861. Culp WT, Ehrhart N, Withrow SJ, et al.: Results of surgical exci-
838. MacEwen EG, Hurvitz AI, Hayes A: Hyperviscosity syndrome sion and evaluation of factors associated with survival time in dogs
associated with lymphocytic leukemia in three dogs, J Am Vet Med with lingual neoplasia: 97 cases (1995–2008), J Am Vet Med Assoc
Assoc 170:1309–1312, 1977. 242:1392–1397, 2013.
839. Matus RE, Leifer CE, Hurvitz AI: Use of plasmapheresis and 862. Sykes SE, Byfield V, Sullivan L, et al.: Feline respiratory extramed-
chemotherapy for treatment of monoclonal gammopathy associ- ullary plasmacytoma with lymph node metastasis and intrahistio-
ated with Ehrlichia canis infection in a dog, J Am Vet Med Assoc cytic amyloid, J Comp Pathol 156:173–177, 2017.
190:1302–1304, 1987. 863. Aoki M, Kim T, Shimada T, et al.: A primary hepatic plasma cell
840. Fan TM, Kitchell BE, Dhaliwal RS, et al.: Hematological toxic- tumor in a dog, J Vet Med Sci 66:445–447, 2004.
ity and therapeutic efficacy of lomustine in 20 tumor–bearing cats: 864. Chaffin K, Cross AR, Allen SW, et al.: Extramedullary plasmacytoma
critical assessment of a practical dosing regimen, J Am Anim Hosp in the trachea of a dog, J Am Vet Med Assoc 212:1579–1581, 1998.
Assoc 38:357–363, 2002. 865. Choi YK, Lee JY, Kim DY, et al.: Uterine extramedullary plasmacy-
841. Farhangi M, Osserman EF: The treatment of multiple myeloma, toma in a dog, Vet Rec 154:699–700, 2004.
Semin Hematol 10:149–161, 1973. 866. Hayes A, Gregory SP, Murphy S, et al.: Solitary extramedullary
842. Lippi I, Perondi F, Ross SJ, et al.: Double filtration plasmapher- plasmacytoma of the canine larynx, J Small Anim Pract 48:288–
esis in a dog with multiple myeloma and hyperviscosity syndrome, 291, 2007.
Open Vet J 5:108–112, 2015. 867. Perlmann E, Dagli ML, Martins MC, et al.: Extramedullary
843. Bartges JW: Therapeutic plasmapheresis, Semin Vet Med Surg (Small plasmacytoma of the third eyelid gland in a dog, Vet Ophthalmol
Anim) 12:170–177, 1997. 12:102–105, 2009.
844. Farrow BR, Penny R: Multiple myeloma in a cat, J Am Vet Med 868. Schoniger S, Bridger N, Allenspach K, et al.: Sinonasal plasmacy-
Assoc 158:606–611, 1971. toma in a cat, J Vet Diagn Invest 19:573–577, 2007.
845. Anderson K, Ismaila N, Flynn PJ, et al.: Role of bone-modifying 869. Van Wettere AJ, Linder KE, Suter SE, et al.: Solitary intracerebral
agents in multiple myeloma: american society of clinical oncology plasmacytoma in a dog: microscopic, immunohistochemical, and
clinical practice guideline update, J Clin Oncol 36:812–818, 2018. molecular features, Vet Pathol 46:949–951, 2009.
846. Mhaskar R, Kumar A, Miladinovic B, et al.: Bisphosphonates in 870. Witham AI, French AF, Hill KE: Extramedullary laryngeal plasma-
multiple myeloma: an updated network meta–analysis, Cochrane cytoma in a dog, N Z Vet J 60:61–64, 2012.
Database Syst Rev 12:CD003188, 2017. 871. Smithson CW, Smith MM, Tappe J, et al.: Multicentric oral plas-
847. Kisseberth WC, MacEwen EG, Helfand SC, et al.: Response to macytoma in 3 dogs, J Vet Dent 29:96–110, 2012.
liposome–encapsulated doxorubicin (TLC D-99) in a dog with 872. Fukumoto S, Hanazono K, Kawasaki N, et al.: Anaplastic atypical
myeloma, J Vet Intern Med 9:425–428, 1995. myeloma with extensive cutaneous involvement in a dog, J Vet Med
848. Ito K, Kobayashi M, Kuroki S, et al.: The proteasome inhibitor Sci 74:111–115, 2012.
bortezomib inhibits the growth of canine malignant melanoma 873. Mayer MN, Kerr ME, Grier CK, et al.: Immunoglobulin A mul-
cells in vitro and in vivo, Vet J 198:577–582, 2013. tiple myeloma with cutaneous involvement in a dog, Can Vet J
849. Araujo KP, Bonuccelli G, Duarte CN, et al.: Bortezomib (PS-341) 49:694–702, 2008.
treatment decreases inflammation and partially rescues the expres- 874. Atherton MJ, Vazquez–Sanmartin S, Sharpe S, et al.: A metastatic
sion of the dystrophin–glycoprotein complex in GRMD dogs, secretory gastric plasmacytoma with aberrant CD3 expression in a
PLoS One 8:e61367, 2013. dog, Vet Clin Pathol 46:520–525, 2017.